Transparency directive : regulatory news

23/08/2017 18:00

21/12/2018 07:00
20/12/2018 17:35
06/12/2018 18:00
15/11/2018 07:00
30/08/2018 07:00
23/08/2018 07:00
20/07/2018 07:00
08/06/2018 07:00
29/05/2018 07:02
09/05/2018 07:00

Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Louvain-la-Neuve, Belgium, August 23, 2017 - IBA (Ion Beam Applications SA), the world`s leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated August 22, 2017.

Communication of the basic data as per Article 15 §1 al.1 of the Law

  • Total capital: EUR 41 938 157,86
  • Total number of securities conferring the voting right: 29 880 251
  • Total number of voting rights (= the denominator): 29 880 251
  • Total number of securities conferring the voting right, by category: N/A
  • Total number of voting rights, by category: N/A

Communication of the additional data as per Article 15 §1 al.2 of the Law

  • Total number of convertible bonds conferring the voting right: 0
  • Total number of rights, materialized or not by certificates, giving the right to subscribe to newly issued securities conferring the voting right (e.g. warrants): 482 148
  • Total number of voting rights which would result from the exercise of these conversion or subscription  rights: 482 148
  • Total number of shares without voting right: 0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA`s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

For further information, please contact:

Stephanie Bauwin
Legal Counsel
+32 10 203 924